Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 4/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | PLK1 | P53350 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2400673 | 0.85 | CYP3A4 (0.43) | TLR8TLR7KITNPC1RAB9A | |
| SCHEMBL2400680 | 0.83 | MAOB (0.45) | MAOBNPC1RAB9AKMT2A | |
| SCHEMBL2399876 | 0.83 | TLR8 (0.53) | TLR8TLR7 | |
| SCHEMBL5765605 | 0.80 | HPGDS (0.40) | TLR8TLR7NPC1RAB9A | |
| SCHEMBL2400489 | 0.77 | MAPT (0.37) | TLR8TLR7MAOBNPC1RAB9A | |
| SCHEMBL2399872 | 0.77 | TLR8 (0.39) | TLR8TLR7KIT | |
| SCHEMBL2400596 | 0.76 | CYP3A4 (0.45) | TLR8TLR7KITNPC1RAB9A | |
| SCHEMBL2399819 | 0.75 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL5090104 | 0.75 | NCF1 (0.36) | TLR8TLR7 | |
| SCHEMBL5767486 | 0.74 | TLR8 (0.42) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006009826-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | IL2, TSLP, IFNG | TLR8 82/4885TLR7 37/4885CSF1R 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.